ResearcherGeorgetown University Medical CenterActive in the last 2 years

Shigekazu Murakami

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5086886001. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114176 ↗
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/onc.2016.288 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chunling Yi · 2 shared papers, 2017–2024 · strength 0.35
- Paper PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer. DOI 10.1016/j.celrep.2024.114176 ↗
- Paper Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. DOI 10.1038/onc.2016.288 ↗
Chan D.K. Nguyen · 1 shared paper, 2024 · strength 0.28
- Paper PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer. DOI 10.1016/j.celrep.2024.114176 ↗
Rishi Surana · 1 shared paper, 2017 · strength 0.07
- Paper Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. DOI 10.1038/onc.2016.288 ↗
Louis M. Weiner · 1 shared paper, 2017 · strength 0.07
- Paper Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. DOI 10.1038/onc.2016.288 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.